Entrada Therapeutics (TRDA) Accumulated Expenses (2020 - 2026)

Entrada Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 54.77% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $11.7 million, a 54.77% increase from a year earlier, with the FY2025 full-year figure at $17.7 million, up 32.52% from the prior year.
• Accumulated Expenses declined to $11.7 million in Q1 2026 per TRDA's latest filing, from $17.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.7 million in Q4 2025 and bottomed at $4.5 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $11.3 million (2023), against an average of $10.6 million.
• Across the five-year window, Accumulated Expenses jumped 158.09% in 2023 and retreated 24.7% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $7.6 million in 2022, then surged by 49.49% to $11.3 million in 2023, then grew by 17.82% to $13.3 million in 2024, then jumped by 32.52% to $17.7 million in 2025, then tumbled by 33.66% to $11.7 million in 2026.
• Per Business Quant, the three latest TRDA Accumulated Expenses figures stand at $11.7 million (Q1 2026), $17.7 million (Q4 2025), and $15.5 million (Q3 2025).